In the News
As reported by The New York Times, December 10, 2006.
Connecticut Takes a Lead in Stem-Cell Research Aid
By Jennifer Medina
FARMINGTON -- One researcher will get $3.5 million to explore how
embryonic stem cells might be used to repair skin, muscles, cartilage
and bones badly injured in war. Another will get a few hundred thousand
dollars to examine ways such cells could repair neurons damaged by
epilepsy and seizures. A third will track their use in treating
Parkinson’s and other degenerative brain diseases.
Doling out $20 million to 21 research projects, Connecticut is moving
faster and further than other states to take the most controversial form
of stem-cell research, that involving tissue from human embryos, from
the political arena to the laboratory. The money will flow beginning
next year, and is just a start: the state has allocated $100 million
over the next decade.
Connecticut leads several states that have started to take more
aggressive steps to support stem-cell research since President Bush
vetoed a provision last summer to spend federal money on it. That veto
came after a White House move in 2001 to restrict federally funded
research to a limited number of stem-cell lines.
Soon California will begin to decide how to distribute nearly $150
million. New Jersey has already awarded nearly $10 million, though most
of the research projects there do not involve embryonic cells; the state
plans to allocate millions more for additional research facilities.
Maryland and Illinois have also agreed to finance stem-cell research.
Private companies and foundations have also paid for some projects.
It will take years, if not decades, for the research proposals
Connecticut is supporting to be translated into clinical trials for
therapies or cures. Each proposal reflects the high expectations for the
use of embryonic cells, which scientists believe can be developed into
any type of body tissue and thus provide the basis for comprehensive
treatments.
Opponents of such research, which uses destroyed embryos, want it to
be severely restricted or banned outright as inhumane.
The first round of grants will pay for research at the University of
Connecticut — which received $12 million, more than half the total —
Yale University and Wesleyan University.
“Certainly we put an emphasis on research that cannot or is not being
done elsewhere, which means embryonic stem cells,” said Dr. J. Robert
Galvin, the commissioner of Connecticut’s Department of Public Health
and chairman of its stem-cell advisory board. “We want to create an
atmosphere here where we are showing that this is welcome in
Connecticut. We are operating under the belief that if we build it, they
will come.”
More than 70 proposals were considered by scientific review boards
before being submitted to the research advisory committee appointed by
the state.
One rejected proposal included a plan to clone a human embryo and use
it to produce new stem cells. Dr. Galvin said that it was turned down
because it received low marks from the review board, and that there was
no vocal opposition to the idea of cloning embryos in principle.
The committee made a special effort to finance scientists who are
only beginning such research.
Dr. David W. Rowe, a professor of genetics and developmental biology
at the University of Connecticut Health Center in Farmington, who will
get $3.5 million for experiments on healing serious war wounds, said he
was confident that such work would bring attention to the university.
Like several other researchers receiving the grants, Dr. Rowe has
done some research using adult stem cells, but is hoping that embryonic
cells will be stronger and more efficient to repair the most serious
wounds.
“What’s going on with soldiers now is that injuries are so
catastrophic, massive injuries and losing large segments of bone,” Dr.
Rowe said. “This really is transformative for us because we can look at
ways of doing things we had only thought about so far.”
Laura Grabel, a professor of biology at Wesleyan, whose $800,000
research project focuses on epilepsy, has done some similar work using
stem cells in mice, and said that using human stem cells would take the
research one step closer to an ability to apply it in patients.
“We’re not anywhere near the level of this happening in humans, and
there are many roadblocks,” Dr. Grabel said. “But there are some models
of the system that look very promising, and we’re just at the very
beginning. This is going to be far beyond what we were able to do
before.”
Like other scientists pushing for such research, Dr. Grabel said she
was thankful for the “extremely supportive political climate” in the
state and said she expected other researchers to take notice.
“There is no question that more money is going to translate into more
research, and we will be in an excellent position to get more dollars
from the federal government if the funds ever become available,” she
said.
While the financing is widely praised in scientific circles and many
advocates view it as a potential boon for local economies, some caution
that financial support from states alone could result in a patchwork and
haphazard approach to the research.
“There are many states moving money around, but the implementation is
not the same everywhere, so while we are grateful for state governments
filling the void, it points to real problems,” said Sean Tipton,
president of the Coalition for the Advancement of Medical Research and a
leading lobbyist in Washington for stem-cell research funding.
“It is quite inefficient to have every state trying to figure out
their own way of how to review grants, spend the money and monitor what
the researchers are doing,” he said.
|